Abstract Library

#4613 Correlation of serum cytokeratin 18, ferritin, cancer antigen 125, and beta-2 microglobulin with tumour grade and stage in pancreatic neuroendocrine tumours

Introduction: Pancreatic neuroendocrine neoplasms (PNENs) remain challenging to diagnose, with limited reliable serum biomarkers available for early detection and prognostication.

Conference:

Presenting Author: Janas K

Authors: Janas K, Rosiek V, Kos-Kudła B,

Keywords: NEN, biomarker, analysis, diagnostic, pancreatic tumour,

#4373 Focal adhesion kinase drives proliferation and invasion in gastrointestinal neuroendocrine tumours via modulation of transformative cell signalling and gene expression

Introduction: Focal Adhesion Kinase (FAK) is a non-receptor protein kinase that localises in both the cytoplasm and nucleus, influencing cell function through its enzymatic and scaffold activities. Through its scaffold function, FAK modulates gene expression epigenetically. Gastrointestinal neuroendocrine tumours (GI-NETs) exhibit a relatively low mutation rate, supporting the hypothesis that these malignancies may be driven epigenetically. Recently, PROTAC (PROteolysis TArgeting Chimeras) technology has enabled selective inhibition and degradation of FAK, providing a novel approach to explore its role in GI-NETs.

Conference:

Presenting Author: Gagliano T

Authors: Toffoli L, Ditsiou A, Moschioni E, Hamm V, Gagliano T,

Keywords: FAK, GI-NET, Cell Signalling, Epigenetics,

#4247 Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia - A case report

Introduction: Idiopathic Diffuse Neuroendocrine Diffuse Neuroendocrine Hyperplasia is a rare, but increasingly recognized entity that primarily affects middle-aged and elderly women, Of available therapies, somatostatin analogs and mTOR are the most promising

Conference:

Presenting Author: Florez A

Authors: Florez A, Unigarro M, Fernandez J, Viola L, Perez G,

Keywords: neuroendocrine tumor, lung, idiopathic diffuse neuroendocrine hyperplasia, tumorlets,

#4232 Aurora kinase A inhibition as a promising therapeutic strategy in ARID1A-mutated neuroendocrine carcinomas: First results of an in vitro and in vivo study

Introduction: Neuroendocrine carcinomas of the gastrointestinal tract (GEP-NEC) are rare but extremely aggressive tumor diseases with a 5-year survival rate of approximately 25%. The inactivating ARID1A mutation can be detected in approximately 40% of cases of GEP-NEC. Previous studies have shown that Aurora kinase A inhibition leads to selective synthetic lethality of ARID1A-deficient colorectal tumor cells.

Conference:

Presenting Author:

Authors: Viol F, Amin T, Sipos B, Fründt T, Smolkova B,

Keywords: Neuroendocrine Carcinoma, Mutation based Therapy, ARID1A, Aurora Kinase A,

#4130 CHGA and DAXX/ATRX expression influence the outcome of pancreatic head neuroendocrine tumors

Introduction: In the past two years a difference between pancreatic neuroendocrine tumors (pNET) located in the head and body/tail regarding biological characteristics and clinical outcomes was described.

Conference:

Presenting Author: Amin T

Authors: Amin T, Viol F, Awwad F, Fründt T, Fraune C,

Keywords: neuroendocrine tumor, pancreatic, DAXX/ATRX, OS,